TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01905059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: monoPI - boosted lopinavir or boosted darunavir
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine
Description: boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
Study: NCT00922259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A H7N7 vaccine
Description: Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10\^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
Study: NCT03766724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
Description: Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
Description: Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
Study: NCT01304381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
Study: NCT03766724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
Description: Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
Study: NCT01304381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
Study: NCT02513368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: augmentation procedure with Bio-Oss® and Bio-Gide®
Description: soft tissue management using GBR procedure
Study: NCT03859128

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
Study: NCT02513368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: augmentation procedure with connective tissue graft
Description: soft tissue management using the bilaminar technique
Study: NCT02397993

Intervention type: PROCEDURE
Intervention: blood collection
Description: blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA

Intervention type: PROCEDURE
Intervention: fine needle aspiration
Description: During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas

Intervention type: PROCEDURE
Intervention: blood collection
Description: blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
Study: NCT02635737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentimark
Description: Placement of a metallic clip with paramagnetic properties for tumour localisation
Study: NCT03326648

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
Study: NCT00878462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
Study: NCT03859128

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
Study: NCT05727449

Intervention type: PROCEDURE
Intervention: General Anesthesia
Description: General Anesthesia was intruduced for Cesarean Delivery

Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: Spinal Anesthesia was intraduced for Cesarean Delivery
Study: NCT04449536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Administration of a single oral dose, using film-coated tablets of either 400 mg or 600 mg or a combination of maximum 3 tablets up to a maximum of 1600 mg
Study: NCT01465282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.05%
Description: 0.05% CT327 (w/w) ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.1%
Description: 0.1% CT327 (w/w) ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 0.5%
Description: 0.5% CT327 (w/w) ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02262195

Intervention type: OTHER
Intervention: Elevated levels of carboxyhemoglobin
Description: Comparison of pulse co-oximeters

Intervention type: OTHER
Intervention: Elevated levels of carboxyhemoglobin
Description: Comparison of pulse co-oximeters
Study: NCT00485030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher
Description: sirolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: sirolimus-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience-V
Description: everolimus-eluting stent
Study: NCT00916500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCURRENT CHEMORADIATION (CISPLATIN)
Description: Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
Study: NCT00485030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience-V
Description: everolimus-eluting stent
Study: NCT04818996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated.
Study: NCT04203121

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose whole brain radiation to treat Alzheimer disease
Description: subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose whole brain radiation to treat Alzheimer disease
Description: subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions
Study: NCT03891758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-IPV
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study: NCT02848040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDK Bile Acids
Description: colourimetric in-vitro laboratory diagnostic test
Study: NCT03747458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study: NCT03198026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT00736086

Intervention type: DEVICE
Intervention: Vessel Closure (StarClose™)
Study: NCT03198026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03382652

Intervention type: DEVICE
Intervention: Metal-on-Metal Articulation
Description: \<Metal-on-Metal Articulation\>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component\>:Continuum Acetabular Shell, \<Femoral Component\>: Zimmer® M/L Taper Hip Stem
Study: NCT03811132

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
Study: NCT03311490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spraino
Description: Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period.
Study: NCT03811132

Intervention type: OTHER
Intervention: Observation
Description: There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
Study: NCT02346669

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fat low fiber diet
Description: as detailed in arm description
Study: NCT02854137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: 10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).

Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: 10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
Study: NCT03271385

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluated by the predetermined differentiating formula
Description: After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluated by the predetermined differentiating formula
Description: After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: evaluated by the predetermined differentiating formula
Description: After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
Study: NCT02346669

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham diet
Description: as detailed in arm description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low fat high fiber diet
Description: as detailed in arm description
Study: NCT00878462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE raspberry flavor (Treatment A)
Description: Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
Study: NCT01251276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Process Hepatitis B Vaccine
Description: Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Process Hepatitis B Vaccine
Description: Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
Study: NCT00538824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for \> 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for \>2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*
Study: NCT01555112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical AS101
Description: AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
Study: NCT00403559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elidel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Cream
Study: NCT00931580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
Study: NCT04897555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
Study: NCT00618761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test
Study: NCT01764867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified electroconvulsive therapy
Description: Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.